Overview

Respiratory syncytial virus (RSV) can cause serious respiratory illness in young infants and some older or vulnerable adults. A newly introduced RSV injection (monoclonal antibody or vaccine, depending on the program) may be offered to reduce the risk of severe RSV disease.

This page summarises eligibility, how the injection works, its benefits and common side effects. For full clinical guidance and up‑to‑date advice, consult the official Rijksvaccinatieprogramma page.

Who is eligible

Eligibility depends on the national programme decisions. Groups often prioritised include:

• Infants at high risk (e.g. premature babies or those with certain heart or lung conditions).
• Older adults or individuals with severe immune compromise (depending on the vaccine type and policy).
• Pregnant women may be offered vaccination to protect infants via maternal antibodies in some programmes.

Check the official schedule for the current recommendations and target groups.

Effectiveness & safety

Clinical studies show that RSV injections (vaccines or monoclonal antibodies) can significantly reduce hospitalisations and severe RSV disease in the target groups. The exact effectiveness varies by product and patient population.

Safety monitoring is in place; the national programme and health authorities continuously review data to ensure benefits outweigh risks.

Common side effects

Typical side effects are mild and short‑lived, and may include:

• Pain, redness or swelling at the injection site
• Low‑grade fever, irritability or drowsiness in infants
• Generalised aches or mild flu‑like symptoms

If you notice severe or unexpected reactions, seek medical attention promptly and report them to your healthcare provider.

FAQ

• Is the injection free? Vaccinations offered by the national programme are usually free for eligible groups.
• When is it given? Timings depend on the chosen schedule — e.g. at birth, during pregnancy or at specified infant ages.
• Can siblings get it? Typically, only recommended target groups receive the injection; consult your public health nurse or GP.
• Where to get it? At your local youth health service (consult the RIVM/Rijksvaccinatieprogramma guidance) or designated vaccination clinics.

Overview

The rotavirus vaccine protects against infection with the rotavirus, which can cause severe gastrointestinal illness, diarrhoea and dehydration in young children. :contentReference[oaicite:0]{index=0}

The vaccine has been added to the Dutch National Immunisation Programme for infants born on or after 1 January 2024. :contentReference[oaicite:1]{index=1}

Vaccination Schedule

Children receive the rotavirus vaccine orally (in drops), not via injection. :contentReference[oaicite:2]{index=2}

• First dose: around 6–9 weeks after birth. :contentReference[oaicite:3]{index=3}
• Second dose: around 3 months of age. :contentReference[oaicite:4]{index=4}

The protection provided by the vaccine lasts for at least 3 years. :contentReference[oaicite:5]{index=5}

Effectiveness

Studies indicate that infants who receive the vaccination have significantly lower rates of hospitalisation due to rotavirus — up to 86–93% reduction compared to unvaccinated children. :contentReference[oaicite:6]{index=6}

Side Effects

Common side effects include mild diarrhoea, irritability, or mild illness. :contentReference[oaicite:7]{index=7}

There is a very rare risk of intussusception (a part of the intestine folding into itself), especially in the first week after vaccination. :contentReference[oaicite:8]{index=8}

Symptoms to watch for: severe abdominal pain, excessive crying, drawing up legs, vomiting, bloody or mucus‑mixed stool. Contact your GP if concerned. :contentReference[oaicite:9]{index=9}

Eligibility & Contra‑indications

• Offered to infants born on or after 1 January 2024. :contentReference[oaicite:10]{index=10}
• Not recommended for infants younger than 6 weeks. :contentReference[oaicite:11]{index=11}
• Maximum age for the first dose: 24 weeks (Rotarix), or 33 weeks for some vaccines. :contentReference[oaicite:12]{index=12}
• Contra‑indications include a history of intussusception, certain intestinal abnormalities, or severe immune deficiency. :contentReference[oaicite:13]{index=13}

The vaccine used in the programme is Rotarix®. :contentReference[oaicite:14]{index=14}

Vaccination Schedule

The DTaP‑IPV‑Hib‑HBV vaccine is given to children at:

• 3 months
• 5 months
• 11 months (or 12 months under the new 2025 schedule) :contentReference[oaicite:1]{index=1}

In some cases, an extra dose is given at 2 months (for example if the mother was not vaccinated against whooping cough during pregnancy, or for premature infants). :contentReference[oaicite:2]{index=2}

Protection & Duration

After completing the three-dose series, children are likely to have long-term protection against Hib, hepatitis B and polio. :contentReference[oaicite:3]{index=3}

Additional booster shots are needed:

• At ~5 years: a DTaP booster for diphtheria, tetanus and whooping cough. :contentReference[oaicite:4]{index=4}
• At ~14 years: a DT‑IPV booster for diphtheria, tetanus and polio. :contentReference[oaicite:5]{index=5}

Side Effects

Common side effects (within a day or two) include: :contentReference[oaicite:6]{index=6}

• Fever
• Crying
• Vomiting
• Sleepiness
• Diarrhoea
• Poor feeding
• Pain, redness or swelling at the injection site

Rarely, serious but temporary reactions may occur:

• Collapse (child goes limp / pale): ~1 in 10,000 after first dose. :contentReference[oaicite:7]{index=7}
• Discoloured areas on legs: ~1 in 10,000. :contentReference[oaicite:8]{index=8}
• Febrile seizure: ~1 in 10,000, typically after the 11-month dose. :contentReference[oaicite:9]{index=9}

These reactions usually resolve quickly and are not harmful long-term. :contentReference[oaicite:10]{index=10}

What’s in the Vaccine

The vaccine contains inactivated (killed) components / parts of:

• Diphtheria toxin (inactivated), tetanus toxin (inactivated).
• Whooping cough (pertussis) bacterial components.
• Inactivated (killed) poliovirus (IPV).
• Polysaccharide from Hib bacteria.
• Hepatitis B surface antigen (HBsAg) — a non-infectious component. :contentReference[oaicite:11]{index=11}

Travel Considerations

If you plan to travel abroad, in most cases the standard vaccination schedule is sufficient. However, for countries with high disease risk, discuss with your youth healthcare provider (JGZ) whether adjustments are needed. :contentReference[oaicite:12]{index=12}

Overview

Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae, which can lead to serious infections such as pneumonia, meningitis and sepsis.

The pneumococcal vaccine reduces the risk of these infections in children and in people who are at higher risk due to underlying conditions.

Who is vaccinated

In the Netherlands, the pneumococcal vaccine is part of the national programme for:

• Infants (as part of the standard childhood vaccination schedule)
• Children and adults with certain risk factors (e.g. chronic illnesses, immune deficiency)

Vaccination Schedule

For healthy infants, the vaccine is normally given in several doses according to the national immunisation schedule.

For risk groups, the schedule may include additional or booster doses depending on individual risk and medical guidance.

Effectiveness

The pneumococcal vaccine has been shown to reduce severe pneumococcal disease by a large margin in vaccinated populations, especially in children and high‑risk adults.

Effectiveness depends on the specific vaccine formulation (number of serotypes covered) and the individual’s health status.

Side Effects

Common side effects are usually mild and may include:

• Pain and redness at the injection site
• Fever
• General fatigue or irritability (in children)

Serious adverse reactions are rare. If you have concerns, consult your healthcare provider.

Overview

MMR stands for Measles, Mumps and Rubella. These are serious viral diseases, but the combined MMR vaccine offers strong protection. ([rijksvaccinatieprogramma.nl](https://rijksvaccinatieprogramma.nl/en/vaccinations/mmr?utm_source=chatgpt.com))

Vaccination Schedule

The MMR vaccine is given in two doses in the Netherlands:

• First dose at 14 months
• Second dose at 9 years

Effectiveness

The MMR vaccine provides very high protection:

• Measles: ~ 95%+ protection after two doses.
• Mumps and rubella: similarly high levels of immunity after vaccination.

Side Effects

Common side effects are mild and may include:

• Pain or swelling at the injection site
• Fever
• Rash (mild)
• Mild joint pain (especially in older children/adults)

Safety & Contra‑indications

The MMR vaccine is considered very safe for most people. However, it may not be recommended if:

• You have a severe immune deficiency.
• You are pregnant (or planning to become pregnant within a short time).
• You had a severe allergic reaction (anaphylaxis) to a previous dose or to any component of the vaccine.

Always discuss any health concerns with your doctor or the youth health service.

Overview

Meningococcal disease (caused by Neisseria meningitidis) can lead to life‑threatening conditions such as meningitis and sepsis. The MenACWY vaccine protects against four major serogroups: A, C, W and Y. :contentReference[oaicite:1]{index=1}

Vaccination Schedule

In the Netherlands, the MenACWY vaccine is administered twice as part of the national programme: :contentReference[oaicite:2]{index=2}

• First dose at ~ 14 months (together with the MMR vaccination) :contentReference[oaicite:3]{index=3}
• Second dose at ~ 14 years old :contentReference[oaicite:4]{index=4}

Side Effects

Possible side effects vary by age: :contentReference[oaicite:5]{index=5}

• **At 14 months**: fever, crying, spitting up, sleepiness, diarrhoea, poor feeding, and local reactions (red, swollen or painful arm) :contentReference[oaicite:6]{index=6}
• **At 14 years**: muscle pain, tiredness, headache, and local arm reactions like redness or swelling :contentReference[oaicite:7]{index=7}
• Rarely: fainting might occur in teenagers after vaccination. :contentReference[oaicite:8]{index=8}

What’s in the Vaccine

The MenACWY vaccine used in the Dutch programme consists of inactivated (conjugate) components from four meningococcal strains (A, C, W and Y). :contentReference[oaicite:9]{index=9}

What is HPV?

HPV (Human Papillomavirus) is a very common virus. Some types (especially HPV-16 and HPV-18) can lead to cancer later in life. :contentReference[oaicite:0]{index=0}

The virus often clears up on its own, but persistent infection with high-risk types can cause cell changes and eventually cancer. :contentReference[oaicite:1]{index=1}

Vaccination Schedule

The HPV vaccine is offered in the year that children turn 10 years old. :contentReference[oaicite:2]{index=2}

Two doses are given, approximately six months apart. :contentReference[oaicite:3]{index=3}

Protection & Effectiveness

The HPV vaccine provides around 95% protection against long-term infection with HPV types 16 and 18. :contentReference[oaicite:4]{index=4}

Types 16 and 18 are those most likely to cause cancers such as cervical cancer. :contentReference[oaicite:5]{index=5}

Side Effects

Common side effects include:

• Pain at the injection site
• Muscle pain
• Sometimes: headache, stomach pain, tiredness or fever

These side effects usually go away within 1–3 days. :contentReference[oaicite:6]{index=6}

FAQ

• Is the vaccination free? Yes — it is offered through the National Immunisation Programme. :contentReference[oaicite:7]{index=7}
• How long does the protection last? At least 15 years according to current data. :contentReference[oaicite:8]{index=8}
• Can I still be vaccinated if I missed it? Yes — HPV vaccination is free up to age 18. :contentReference[oaicite:9]{index=9}
• What about the new 9‑valent HPV vaccine? The Netherlands plans to switch to the 9‑valent vaccine in the autumn of 2026. :contentReference[oaicite:10]{index=10}

Why people are hesitant

Some of the reasons people hesitate include fear of side-effects, mistrust in authorities, religious or philosophical beliefs, and the feeling that vaccination is not necessary.

These concerns are natural — thoughtful discussion, transparent information, and professional advice help many make a confident decision.

Misinformation & Myths

There are many false claims that circulate about vaccines. Examples include:

• Vaccines cause the disease they prevent.
• Vaccines overload the immune system.
• Vaccines contain harmful substances in dangerous amounts.

Scientific evidence consistently shows that vaccines go through rigorous safety testing and monitoring after approval.

Common Questions

• Are vaccines safe? Yes — vaccines used in the national programme are tested heavily and monitored afterwards.
• Can I wait and see? That’s a valid approach, but delaying vaccination can leave you or your child unprotected.
• What about long‑term effects? Long-term safety monitoring is a key part of vaccination programmes; serious long-term effects are extremely rare.
• Can I talk to someone trusted? Yes — you can speak with a doctor, youth healthcare nurse (JGZ), or get reliable information through public health organisations.

Where to get help

If you're hesitant, you can:

• Talk to your general practitioner (GP) or youth health nurse (JGZ).
• Use official vaccine information websites (e.g., RIVM, Rijksvaccinatieprogramma).
• Attend information sessions or webinars organized by healthcare providers.
• Use reliable tools to assess the risks and benefits.

Making a decision can take time — it’s okay to ask questions and seek clarity.

The Study

Researchers at Radboud University Medical Centre surveyed parents of children younger than three months. A total of 533 parents completed a questionnaire about their background, values and attitudes toward vaccinations. :contentReference[oaicite:0]{index=0}

Main Findings

• 27% of parents indicated some degree of hesitancy about national immunisation schedule. :contentReference[oaicite:1]{index=1}
• Hesitancy was more common among parents with lower education, religious or anthroposophical backgrounds, and younger parents. :contentReference[oaicite:2]{index=2}
• At 6 months of age, 403 out of 423 children (of the hesitant group) were vaccinated according to schedule for serious diseases like polio, diphtheria, and whooping cough. :contentReference[oaicite:3]{index=3}

Implications

The overall vaccination rate is declining in the Netherlands, and in 2022 dropped below 90% for children up to two years old, increasing risk of outbreaks. :contentReference[oaicite:4]{index=4}

Understanding the characteristics and values of hesitant parents can help public health professionals tailor communication and support strategies.

Support for Parents

Researchers emphasize that it's important to take doubts seriously and to engage with parents early — for instance during pregnancy — so they feel heard and informed when making vaccination decisions. :contentReference[oaicite:5]{index=5}

Diseases Covered

The programme protects against a range of serious infectious diseases: diphtheria, whooping cough (pertussis), tetanus, polio, Hib, pneumococcal disease, hepatitis B, mumps, measles, rubella, rotavirus, RSV, meningococcal disease (ACWY), and HPV. :contentReference[oaicite:0]{index=0}

Vaccination Schedule

Infants in the Netherlands receive their first vaccinations at 3 months old, when their immune system is ready to respond. :contentReference[oaicite:1]{index=1}

The schedule is designed for maximum protection at vulnerable ages. :contentReference[oaicite:2]{index=2}

Cost & Participation

The National Immunisation Programme is free of charge for participants. :contentReference[oaicite:3]{index=3}

Participation is voluntary, but uptake is high: over 95% of parents agree to have their children vaccinated. :contentReference[oaicite:4]{index=4}

Monitoring & Research

RIVM monitors vaccine uptake, disease incidence and safety. :contentReference[oaicite:5]{index=5}

An annual surveillance report (2023‑2024) highlights trends and updates in the programme. :contentReference[oaicite:6]{index=6}

Features

• Video calling with your GP
• Make appointments
• Send messages securely to your GP or pharmacist
• View laboratory results
• Order repeat prescriptions

All these services are available via the MedGemak app or the web portal. :contentReference[oaicite:1]{index=1}

Login

You can log in with DigiD (SMS or DigiD app) to access MijnGezondheid.net. :contentReference[oaicite:2]{index=2}

If you don’t have an account, your GP or pharmacy must first register you. :contentReference[oaicite:3]{index=3}

MedGemak App

The MedGemak app is an extension of MijnGezondheid.net that lets you manage your health from your smartphone. :contentReference[oaicite:4]{index=4}

Privacy & Security

Your data is protected with a secure DigiD login. :contentReference[oaicite:5]{index=5}

The provider of MijnGezondheid.net is PharmaPartners, certified with ISO 27001 / NEN 7510. :contentReference[oaicite:6]{index=6}

What You Can Do with Helena

• Receive and view prescriptions, lab results, and medical reports. :contentReference[oaicite:1]{index=1}
• Reserve prescribed medication in your favorite pharmacy. :contentReference[oaicite:2]{index=2}
• Have secure conversations with your doctor, including video consultations. :contentReference[oaicite:3]{index=3}
• Manage your care team – invite family members or other providers, and control who sees your data. :contentReference[oaicite:4]{index=4}

How to Get Started

You can create an account for free:

1. Go to the Helena website: helena.care :contentReference[oaicite:5]{index=5}
2. Activate your account via **itsme®** or **eID**. :contentReference[oaicite:6]{index=6}
3. Ask your GP or health professional to connect so your medical documents can appear in your Helena account. :contentReference[oaicite:7]{index=7}
4. If you want to connect your pharmacy, scan the QR code at your pharmacy on the Helena app. :contentReference[oaicite:8]{index=8}

Login Options

You can log in with itsme® or eID. After first login, you can choose a 6-digit PIN code to make future access easier. :contentReference[oaicite:9]{index=9}

Privacy & Security

Helena is hosted in a secure environment (ISO 27001) and encrypts your health data. :contentReference[oaicite:10]{index=10}

You decide which healthcare providers can see your data, and you remain in control. :contentReference[oaicite:11]{index=11}